Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Latest News

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

View Press Release View All News

Latest Presentation

Corporate Overview

View Presentation View All Presentations

Recent Event

Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

View All Events

Latest Financial Results

FY 2025

Fiscal Year Ended Dec 31, 2025
Earnings Release
PDF HTML
10-K Filing
PDF HTML
XBRL
ZIP HTML

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Report Links

Company Overview

ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.

View Management Team View Board of Directors

Toronto, Canada Office

Address

1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2
Canada

Cambridge, MA U.S. Office

Address

Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142
U.S.A.